BDSX - Biodesix Inc logo

Biodesix Inc

BDSX

Biodesix, Inc. provides diagnostic solutions focused on lung cancer, offering blood tests like Nodify XL2 and GeneStrat to assess malignancy risk and guide treatment decisions. It also supports biopharmaceutical companies with research and diagnostic development services.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago →$156today

Score Overview

1 Year
Score
Net Growth21.28%
Net TrendGrew
Net Income Consistency—
Rev Growth16.32%
Rev TrendGrew
Revenue Consistency—
5 Years
Score6.7
Net Growth35.68%
Net Trend80%
Net Income Consistency—
Rev Growth88.86%
Rev Trend80%
Revenue Consistency—
All Time
Score
Net Growth11.44%
Net Trend67%
Net Income Consistency
Rev Growth125.96%
Rev Trend83%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Biodesix Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. BDSX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 23.94—
1 Year2025-10-22
$ 6.00299.00%
5 Years2021-10-22
$ 153.80-84.43%
All Time2020-10-28
$ 256.20-90.66%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 102M-$ 27M$ 29M
2025$ 88M-$ 35M$ 18M
2024$ 71M-$ 42M$ 26M
2023$ 49M-$ 52M$ 26M
2022$ 38M-$ 65M$ 43M
2021$ 54M-$ 43M$ 32M
IPO2020$ 45M-$ 31M$ 62M
BDSX - Biodesix Inc logo

Biodesix Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 45M to $ 88M and net income went from -$ 31M to -$ 35M. Revenue increased in 4 of those 5 years; net income in 4.

Biodesix Inc currently holds a 5-year HDB Score of 6.7 out of 10. How the HDB Score is calculated.

Membership

Explore BDSX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies